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A B S T R A C T
TLR7 agonists are of high interest for the treatment of cancer, auto-immunity and chronic viral infections. They
are known to activate plasmacytoid dendritic cells (pDCs) to produce high amounts of Type I Interferon (IFN)
and to facilitate T and B cell responses, the latter with the help of maturation markers such as CD40, CD80 and
CD86. The TLR7 single nucleotide polymorphism (SNP) rs179008 (GLn11Leu), sex and chronic viral infection
have all been reported to inﬂuence pDC IFN production. It is unknown, however, whether these factors also
inﬂuence pDC phenotypic maturation and thereby IFN-independent pDC functions. Furthermore, it is unclear
whether SNP rs179008 inﬂuences HBV susceptibility and/or clearance.
Here we investigated whether the SNP rs179008, sex and HBV infection aﬀected phenotypic maturation of
pDCs from 38 healthy individuals and 28 chronic HBV patients. In addition, we assessed SNP prevalence in a
large cohort of healthy individuals (n= 231) and chronic HBV patients (n= 1054).
Consistent with previous reports, the rs179008 variant allele was largely absent in Asians and more prevalent
in Caucasians. Among Caucasians, the SNP was equally prevalent in healthy and chronically infected males. The
SNP was, however, signiﬁcantly more prevalent in healthy females than in those with chronic HBV infection (42
versus 28%), suggesting that in females it may oﬀer protection from chronic infection. Ex vivo experiments
demonstrated that induction of the co-stimulatory molecules CD40 and CD86 by TLR7 ligands, but not TLR9
ligands, was augmented in pDCs from healthy SNP-carrying females. Furthermore, CD80 and CD86 upregulation
was more pronounced in females independent of the SNP. Lastly, our data suggested that chronic HBV infection
impairs pDC maturation. These ﬁndings provide insight into factors determining TLR7 responses, which is im-
portant for further clinical development of TLR7-based therapies.
1. Introduction
Toll Like Receptor 7 (TLR7) is of interest as a therapeutic target for
chronic viral infections, including those with Human
Immunodeﬁciency virus (HIV), Hepatitis B virus (HBV) and Hepatitis C
virus (HCV), and also for other non-infectious diseases such as cancer,
asthma and autoimmunity (Savva and Roger, 2013; Funk et al., 2014;
Boonstra et al., 2011). The TLR7 gene is located on the X-chromosome.
The receptor is expressed intracellularly on plasmacytoid dendritic cells
(pDCs) and recognizes viral single stranded RNA (Gibson et al., 2002).
Besides TLR7, human pDCs also express autosomal TLR9 recognizing
unmethylated CpG DNA (Krug et al., 2001). Upon TLR ligation, pDCs
secrete high amounts of Interferon α (IFNα) inducing a potent anti-viral
response in neighboring cells (Funk et al., 2014). In addition, TLR li-
gation induces pDC phenotypic maturation, characterized by upregu-
lation of co-stimulatory molecules such as CD40, CD80 and CD86 and
by the secretion of pro-inﬂammatory cytokines (Gibson et al., 2002;
Krug et al., 2001). Via these and other receptors and cytokines, pDCs
communicate with other immune cells and exert also IFN-independent
immune functions, such as antigen presentation to T cells or facilitating
B cell diﬀerentiation (Mathan et al., 2013). Both the induction of IFNα
and adaptive immunity by pDCs are considered important for TRL7
https://doi.org/10.1016/j.antiviral.2018.06.015
Received 15 January 2018; Received in revised form 21 June 2018; Accepted 25 June 2018
∗ Corresponding author.
E-mail address: A.Woltman@erasmusmc.nl (A.M. Woltman).
Antiviral Research 157 (2018) 27–37
Available online 28 June 2018
0166-3542/ © 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
T
agonists to combat viral infection (Funk et al., 2014; Swiecki et al.,
2010). To optimize and personalize treatment and to select patients that
beneﬁt most from TLR7 agonist treatment, it is important to understand
how genetic and environmental factors inﬂuence the response of pDCs
to TLR7 agonists.
Previously, the TLR7 SNP rs179008 (A/T; Gln/Leu) has been shown
to alter TLR7 function. PBMCs from males carrying the variant T allele
secreted less IFNα upon TLR7 ligation than those from males with the
more common A (i.e. WT) allele (Oh et al., 2009). Furthermore, in HIV,
the variant allele associated with higher infection rates, viral load and
disease progression (Oh et al., 2009; Said et al., 2014). In HCV, the
variant was more prevalent among chronic patients as compared to
healthy controls and related to a poor IFNα treatment response (Schott
et al., 2007a; Askar et al., 2010). For HBV, the prevalence of the variant
allele among chronic patients has not yet been explored.
pDC function is also aﬀected by sex: male pDCs, as compared to
female pDCs, produce less IFNα upon TLR7 but not TLR9 ligation
(Berghöfer et al., 2006; Meier et al., 2009). This diﬀerence is believed to
derive from expression diﬀerences of X-chromosomal genes down-
stream of TLR7, combined with hormonal eﬀects (Seillet et al., 2012,
2013; Griesbeck et al., 2015). In addition, chronic HBV (CHB) infection
itself can also impair pDC function; HBV impairs IFNα secretion and
other pDC functions in response to TLR9 ligation (Woltman et al., 2011;
Martinet et al., 2012a, 2012b). Whether rs179008, sex or CHB aﬀect
pDC phenotypic maturation in response to TLR7 ligands is not known.
Here we performed an elaborate screen of healthy individuals and
CHB patients for their rs179008 genotype. In addition, on PBMCs from
healthy and CHB patients, we assessed how this SNP, sex and CHB in-
ﬂuence TLR-ligand induced pDC phenotypic maturation. Our results
indicate that for CHB the rs179008 variant is not a risk factor and is
even underrepresented in Caucasian female patients. On pDCs, both
CD40 and CD86 were more induced on variant carrying females.
Upregulation of co-stimulatory molecules on pDCs in response to TLR7,
but not TLR9, was signiﬁcantly higher in females than in males. Lastly,
our results suggest that in CHB patients TLR7 ligand-induced pDC
maturation may be suppressed. Together, these data demonstrate that
rs179008 genotype, sex and chronic viral infection inﬂuence the re-
sponse to TLR7 agonist therapy or pathogens that act via TLR7.
2. Methods
2.1. Sample collection and rs179008 genotyping
Blood samples were collected in EDTA or SST tubes. Patients were
either CHB patients attending the outpatient clinic of Erasmus MC
(Rotterdam, The Netherlands), participants in the 99-01 or PARC study
(Janssen et al., 2005; Rijckborst et al., 2010), or members of the Chi-
nese community participating in viral hepatitis outreach screening
events (Antwerp, Belgium). The study was conducted in accordance
with the Declaration of Helsinki and the principles of Good Clinical
Practice. Written informed consent was obtained from all individuals.
The ethical review board of Erasmus MC (Rotterdam, the Netherlands)
and Antwerp University Hospital (Belgium) approved use of archived
serum for this study.
Competitive allele-speciﬁc PCR assays (KASP, LGC genomics,
Huddleston, UK) were employed for the detection of the reference SNP
TLR7 rs179008. Whole blood or serum samples stored at −20 °C or
−80 °C were used for DNA extraction and genotyping procedures,
which were carried out centrally at LGC genomics as before (Brouwer
et al., 2014; Maan et al., 2015). Puriﬁed genomic DNA was used for
genotyping. The genotype sequence was derived from NCBI.
2.2. Flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated from
venous blood by Ficoll density centrifugation (Ficoll-Paque™ plus,
Amersham) and frozen at −150 °C. PBMC were thawed and washed
with RPMI Glutamax medium (Life Technologies) with 10% fetal calf
serum (FCS; Sigma). 1,000,000 PBMC were stimulated in a 96-well
plate in 250 μl RPMI glutamax medium containing 10% FCS, 100 U/ml
penicillin/streptavidin (Gibco) and 10mM Hepes (Lonza) using various
stimuli. The cells were incubated with 20 ng/ml IL-3 (Miltenyi) alone or
in combination with either 10 μg/ml CpG-A (Invivogen), 0.4 mM
Loxoribin (Invivogen) or 0.5 μg/ml R848 (Invivogen). For all condi-
tions, cells were stimulated for 24 h at 37 °C, 5% CO2. Cells were stained
with anti-CD123-APC (clone AC145; Miltenyi), anti-CD304-PerCP-Cy-
5.5 (clone 12C2; Biolegend), anti-CD11c-Pe-Cy7 (clone 3.9;
eBioscience), anti-CD80-FITC (clone MAB104; Beckman Coulter), anti-
CD86-V450 (clone 2331; BD) and anti-CD40-PE (MAB89; Beckman
Coulter). Data was acquired on a Canto II (BD) and analyzed using
Flowjo (version 10.1 Tree Star Inc). pDCs were deﬁned as CD11c-
CD123 + CD304 + within the lymphocyte gate as depicted in Fig. S1.
2.3. Statistical analysis
For statistical analysis ﬂow cytometry-derived mean ﬂuorescence
intensities (MFI) were ﬁrst log10-transformed and then ﬁtted in linear
mixed models in the R programming environment. Models included
interaction terms between TLR eﬀect and SNP, disease status (HBV or
healthy) or sex and separate terms for sex, age and ethnicity. To test if
the eﬀect of TLR ligation was diﬀerent between SNP genotypes, healthy
individuals and HBV patients or between sexes, the model was ﬁtted
with and without these interaction terms. The eﬀect on model ﬁt was
assessed using a likelihood ratio test (LRT). In case inclusion of inter-
action terms signiﬁcantly improved model ﬁt, regression coeﬃcients
and corresponding standard errors, p-values and adjusted p-values
(corrected for multiple testing using the Holms procedure) were cal-
culated from the model with that interaction term (Holm, 1979).
3. Results
3.1. Population prevalence of rs179008 genotypes
To assess the prevalence of the rs179008 variant across diﬀerent
ethnicities we genotyped a large number of healthy donors and CHB
patients. The SNP was successfully genotyped in 176 (out of 231)
healthy donors and 994 (out of 1054) CHB patients. First, we compared
our data to that of a published large genome-wide screen on genetic
variation across many diﬀerent ethnic backgrounds (Auton et al.,
2015). We assessed SNP prevalence between cohorts for the various
ethnicities separately to exclude that the ethnical composition of the
cohorts would inﬂuence SNP prevalence. The prevalence of the SNP
variant (T) in our own healthy cohort (from Rotterdam and Antwerp;
Healthy EA)) was nearly identical to that in the published database
(Healthy DB) which contained rs179008 information of over 2000 in-
dividuals (Table 1; Fig. 1). In both cohorts the variant was most present
in Caucasians (21–22% in males and 42–43% in females) and almost
absent from Asians. The higher prevalence in females can be attributed
to the X-chromosomal location of the TLR7 gene. (Table 1; Fig. 1).
Overall, male CHB patients carried the variant with a comparable fre-
quency as healthy males. Interestingly, the variant was signiﬁcantly
more prevalent in healthy Caucasian females (∼42% in both cohorts)
compared to Caucasian female CHB patients (28%). Heterozygous fe-
males were almost twofold more prevalent in the healthy cohorts (TA:
37% in healthy versus 21% in CHB). Thus, in Caucasian females the
variant (T) allele may oﬀer protection from CHB development.
3.2. Eﬀect of rs179008 genotype on pDC phenotypic maturation
Next, we studied the eﬀect of rs179008 genotype on pDC pheno-
typic maturation. Based on rs179008 genotype, sex, age and sample
availability, we selected PBMCs for in vitro stimulation. We analyzed
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PBMC samples from 20 healthy individuals (10F/10M) carrying the WT
allele only (A or AA), and 10 heterozygous (TA) females. Due to the low
prevalence of the variant, we only had available PBMCs of 8 healthy
individuals (2F/6M) homo- or hemizygous for the variant (T or TT;
Table S1). WT individuals were chosen to match the age of those car-
rying the variant.
After thawing, PBMCs were cultured in the presence or absence of
TLR-ligands Loxoribin (Lox; TLR7), R848 (TLR7 & TLR8) and CpG
(TLR9) and after 24 h the levels of CD40, CD80 and CD86 were assessed
by ﬂow cytometry (Fig. S1). Lox, R848 and CpG all signiﬁcantly in-
creased expression levels of one or more surface markers (Fig. 2A).
Percentages of positive cells were also increased, but skewed towards
“all positive” (Fig. S2). Therefore we used expression levels for further
statistical analysis. Lox and R848 potently induced CD40 and CD86,
while CpG hardly induced CD86, but upregulated CD40 and CD80. Lox,
but not R848, also induced expression of CD80. Plotting samples from
the two sexes separately indicated that CD40 and CD80 expression le-
vels were signiﬁcantly higher in females and this was most clear after
TLR7/8 ligation (Fig. 2B). In contrast, expression levels of CD86 were
higher in males, both at baseline and after TLR9 ligation. Next, to ex-
amine the eﬀect of rs179008 genotype on TLR-ligand induced pDC
maturation we ﬁtted linear mixed models including and excluding SNP
genotype information and determined the eﬀect on model ﬁt using
likelihood ratio tests (LRT). In this analysis samples from one individual
were matched and age and sex were included in the models to reduce
confounding eﬀects. LRTs indicated that both CD40 and CD86, but not
CD80, upregulation (i.e. expression change relative to subject-matched
cells cultured without TLR ligands) was inﬂuenced by rs179008
genotype (Table 2). Closer inspection revealed that pDCs from hetero-
zygous (TA) females signiﬁcantly more upregulated CD40 and CD86
upon TLR 7/8 ligation, compared to WT individuals (A and AA; Table 2,
Fig. 3). Homo- or hemizygous presence of the variant allele (TT or T)
did not appear to aﬀect CD40 and CD86 upregulation compared to WT,
but for these genotypes samples were limited. CpG-induced pDC ma-
turation was less inﬂuenced by the SNP (Table 2; Fig. 3). Together these
data indicate that TLR7/8 induced maturation of pDCs from females in
general, but especially of rs179008 heterozygous females, was aug-
mented.
3.3. Eﬀect of sex on pDC phenotypic maturation
Next, we investigated the eﬀect of sex on pDC phenotypic matura-
tion. Regression analysis demonstrated for all three co-stimulatory re-
ceptors that model ﬁt was signiﬁcantly improved by including the in-
teraction between sex and TLR-eﬀect (Table 3). All receptors were
upregulated more on female pDCs, but only upon TLR7/8 ligation
(Table 3 and Fig. 4). Because the rs179008 heterozygous genotype (TA)
only occurs in females, SNP genotype will contribute to, or could even
explain, this eﬀect of sex. Directly comparing pDCs from homo- and
heterozygous females (AA vs TA; Fig. 3 red symbols only) as well as
comparing males and females carrying only the WT allele (A vs AA;
Fig. 3 black versus red) suggested that the higher upregulation of CD40
in females may be fully attributed to the SNP, while for CD86 the SNP
may not be fully responsible. For CD80, as previously indicated, the
SNP does not seem to contribute at all (Table 2). To further isolate the
sex from the SNP eﬀect, we performed regression analysis on males and
Table 1
TLR7 rs179008 Genotype Distribution in Healthy individuals and HBV patients.
Gender Ethnicity Dataset b A/AA (%) AT T/TT (%) T (%) vs HBV (RA) p-valuec vs Healthy (RA) p-valuec
Male Combined Healthy (DB)a 1100 (89.2) – 133 (10.8) 10.8 – –
Healthy (RA)b 50 (89.3) – 6 (10.7) 10.7 – –
HBV (RA) 566 (85.8) – 94 (14.2) 14.2 – –
Caucasian Healthy (DB) 189 (78.8) 51 (21.3) 21.3 0.5192 1
Healthy (RA) 21 (77.8) – 6 (22.2) 22.2 0.6149 –
HBV (RA) 256 (81.3) – 59 (18.7) 18.7 – 0.6149
Turkish Healthy (DB) – – – – – –
Healthy (RA) – – – – – –
HBV (RA) 63 (86.3) – 10 (13.7) 13.7 – –
Asian Healthy (DB) 489 (97) 15 (3.0) 3.0 – –
Healthy (RA) 27 (100) – 0 (0.0) 0.0 – –
HBV (RA) 133 (100) – 0 (0.0) 0.0 – –
Other Healthy (DB) – – – – –
Healthy (RA) 2 (100) – – 0.0 – –
HBV (RA) 114 (82.0) – 25 (18.0) 18.0 – –
Female Combined Healthy (DB) 989 (77.8) 251 (19.7) 31 (2.4) 22.2 – –
Healthy (RA) 95 (79.2) 22 (18.3) 3 (2.5) 20.8 – –
HBV (RA) 277 (82.9) 47 (14.1) 10 (3.0) 17.1 – –
Caucasian Healthy (DB) 151 (57.4) 98 (37.3) 14 (5.3) 42.6 0.0198 1
Healthy (RA) 33 (57.9) 21 (36.8) 3 (5.3) 42.1 0.101 –
HBV (RA) 60 (72.3) 17 (20.5) 6 (7.2) 27.7 – 0.0198
Turkish Healthy (DB) – – – – – –
Healthy (RA) 4 (80.0) 1 (20.0) – 20.0 – –
HBV (RA) 31 (68.9) 11 (24.4) 3 (6.7) 31.1 – –
Asian Healthy (DB) 476 (95.6) 21 (4.2) 1(0.2) 4.4 – –
Healthy (RA) 55 (100.0) 0 (0.0) 0 (0.0) 0.0 – –
HBV (RA) 121 (98.4) 2 (1.6) 0 (0.0) 1.6 – –
Other & Unknown Healthy (DB) – – – – – –
Healthy (RA) 3 (100) – – 0.0 – –
HBV (RA) 65 (78.3) 17 (20.5) 1 (1.2) 21.7 – –
a Data from the “1000 genomes project” database (DB). Caucasians are all Europeans from this DB. East and south Asia were pooled.
b Data from healthy controls and HBV patients collected in Rotterdam and Antwerp (RA).
c Prevalence of variant allele carrying individuals in the two cohorts being compared by Fisher exact test.
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females carrying the WT allele only (A versus AA; blue symbols in
Fig. 4). For CD80 and CD86 regression analysis indicated a remaining
eﬀect of sex on model ﬁt within SNP WT samples. Closer inspection
revealed that an interaction between sex and TLR7/8 ligand treatment
remained also in this patient sub-group, but was reduced to a trend
(p < 0.1) after applying multiple testing correction (Table 4). CD40
upregulation within the SNP WT samples was not aﬀected by sex.
In summary, pDCs from females more profoundly upregulated all
maturation markers upon TLR7/8 ligation, which for CD40, and to a
lesser extend for CD86, could be attributed to the rs179008 TA geno-
type.
3.4. Eﬀect of CHB on pDC phenotypic maturation
Lastly, we assessed pDC maturation in CHB patients. We retrieved
PBMC samples from 28 CHB patients, 19 (10F/9M) carrying the WT
genotype only, 6 heterozygous females and 3 carrying the variant only
(1F/2M). While the healthy cohort consisted mostly of Caucasians,
approximately half of our CHB cohort was of Turkish decent, including
most females (Table S1). The imbalanced distribution of ethnicities
over sexes did not allow proper evaluation of the eﬀect of sex or
rs179008 genotype within this cohort (Table S1). In CHB patients,
however, we observed a rather low induction of maturation markers,
especially of CD40 (Fig. 5A). Direct comparison of the healthy and CHB
cohorts by regression analysis, taking into account sex and ethnicity,
suggested that CD40 upregulation by TLR7 ligands may indeed be im-
paired in CHB patients (Fig. 5B and Table 5). Inspection of viral and
patient parameters (HBsAg, HBV DNA, ALT) did not reveal any causal
relation between these parameters and this impairment (data not
shown).
4. Discussion
Our results demonstrate that rs179008 may reduce the risk of het-
erozygous Caucasian females to develop CHB, and that the
heterozygous SNP genotype and female sex together positively inﬂu-
ence pDC phenotypic maturation, while CHB impairs pDC maturation.
Our data adds to previous reports on the inﬂuence of sex on pro-
duction of IFNα by pDCs, demonstrating that also surface maturation
markers are upregulated more in female pDCs (Berghöfer et al., 2006;
Meier et al., 2009; Seillet et al., 2012, 2013). The eﬀect of sex on up-
regulation of especially CD40 but also CD86 was respectively mostly or
partially explained by the rs179008 variant allele. For CD80 only an
eﬀect of sex was observed that was independent of rs179008 genotype.
Although we applied stringent statistical criteria to reach our con-
clusions, the limited number of samples in our study may have caused
us to miss less pronounced eﬀects. Furthermore, analysis of the eﬀect of
sex and rs179008 in CHB patients was hampered by diﬀerences in
ethnicities between the sexes in this cohort. For more deﬁnitive con-
clusions on TLR7 function in CHB patients, therefore, additional studies
are needed.
Our observations that the rs179008 variant may protect against
CHB in Caucasian females is contrasting previous ﬁndings for HCV and
HIV. In both infections, the variant allele associated with higher disease
prevalence and augmented disease progression, and with reduced re-
sponse to IFNα-therapy for HCV (Oh et al., 2009; Said et al., 2014;
Askar et al., 2010; Schott et al., 2007b; Fakhir et al., 2018). In all these
studies, eﬀects were most prominent in (mostly rs179008 hetero-
zygous) females and all studies predominantly contained Caucasian
individuals. The fact that HCV and HIV, but not HBV, have been re-
ported to activate TLR7 and pDCs, could contribute to the contrasting
observations for these diseases (Woltman et al., 2011; Beignon et al.,
2005; Takahashi et al., 2010). To conﬁrm that rs179008 SNP is truly
protective for CHB, our study needs to be repeated in a larger cohort.
This cohort preferably should also contain patients spontaneously
clearing the disease, similar to a recent study performed on TLR9 SNPs
in HCV disease progression (Fischer et al., 2017).
In HCV, the rs179008 variant associated with lower levels of IL-10
and Type III IFNs in infected liver tissue, while healthy donor pDCs
carrying the variant displayed impaired IFNα production (Oh et al.,
Fig. 1. TLR7 rs179008 Genotype Distribution in Healthy individuals and HBV patients. Visualization of the most important ﬁndings in Table 1.
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2009; Askar et al., 2010). These are the only reported eﬀects of the SNP
at the protein/cellular level and these data were mostly (for livers), or
completely (for pDCs), derived from hemizygous males. As stated
above, however, most reported clinical eﬀects of the SNP are observed
in females (Oh et al., 2009; Schott et al., 2007b). We also identiﬁed
eﬀects of the SNP only in females. Unfortunately, we could not assess
IFNα secretion to reunite these studies, because we relied on pDCs from
a biobank and IFNα secretion is hampered by cryopreservation (Ida
et al., 2006).
Incomplete X-inactivation of TLR7 may contribute to the eﬀects of
sex. Although previous studies found no evidence for incomplete or
skewed X-inactivation this was recently challenged by Souyris and
colleagues who reported that pDC express more TLR7 in females due to
escape of X-inactivation (Schott et al., 2007a; Berghöfer et al., 2006;
Souyris et al., 2018). Besides, TLR7 function may be enhanced by fe-
male hormones and/or enhanced expression of molecules downstream
of TLR7 (Seillet et al., 2012, 2013; Griesbeck et al., 2015). It remains
unclear why possession of a heterozygous genotype oﬀers an advantage
when it comes to pDC maturation and reducing CHB risk. Possibly, pDC
heterogeneity may facilitate their diverse functions in innate and
adaptive immunity.
Because we stimulated PBMCs rather than pDCs, also other immune
cells contributed to pDC maturation via cytokines or membrane re-
ceptors, as would occur in vivo. Previously, we reported on indirect
eﬀects of other cells in culture (Woltman et al., 2011; van der Aa et al.,
2015). TLR7/8 ligand R848 also activates monocytes and other DC-
subsets expressing TLR8 (or TLR7 upon activation) which indirectly
contributes to the activation of pDCs (Schreibelt et al., 2010; Hou et al.,
2014; Giltiay et al., 2016). Dissecting direct and indirect eﬀects requires
additional experiments with sorted pDCs, which are not feasible due to
insuﬃcient fresh PBMC of rs179008 genotyped individuals.
Recently, two studies reported that pDCs sorted based on the ab-
sence of CD11c and expression of CD123 and BDCA4, as was also our
strategy and common practice until recently, are contaminated by a
Fig. 2. Eﬀect of the rs179008 SNP on the expression level of maturation markers on pDCs from healthy donors. (A)Mean ﬂuorescent intensities (MFI) of
CD40, CD80 and CD86 after 24 h in the presence of absence of indicated TLR-ligands or medium alone (B) Data as in A but for males (M) and females (F) separately
and color coded for the rs179008 TLR7 SNP. P-values ***<0.001, **<0.01 and *<0.05 by paired t-tests comparing TLR-ligand activated pDCs to medium
cultured pDCs (A) or by unpaired t-tests comparing pDCs from males to those of females for each condition (B), all test were performed on log transformed data. Non-
signiﬁcant results are not shown. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
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population of pre-cDCs expressing AXL that highly expresses co-sti-
mulatory molecules (See et al., 2017; Villani et al., 2017). Although it
can be deduced from these studies that bona ﬁde pDCs still outnumber
contaminating cDCs using this gating strategy, it is not known whether
the extent of pre-cDC contamination varies between males and females
or whether it is aﬀected by infection. Therefore, we do not know if pre-
cDCs have inﬂuenced our results. Future studies should address this
issue.
Recently, oral TLR7 ligands successfully induced viral control in
Woodchuck and chimpanzee HBV-animal models (Menne et al., 2015;
Lanford et al., 2013). Disappointingly in humans, oral TLR7 ligands
thus far have not achieved any beneﬁcial eﬀect, despite that treatment
was well tolerated (Gane et al., 2015; Janssen et al., 2017). It is not
clear why clinical beneﬁt in CHB patients was lacking, but impaired
patient TLR7 responses could have contributed. Of note, these studies
mainly included Asians and males and therefore only very few
rs179008 variant carrying individuals and even less to no SNP hetero-
zygous females were treated.
Future studies are needed to determine the functional consequences
of the variation in pDC maturation. Eﬀects were most prominent for
Table 2
Interaction of TLR7 SNP rs179008 with TLR-ligand induced pDC maturation in healthy individuals.
CD40 CD80 CD86
rs179008 LRT p- value: 0.0003 0.2465 0.0082
Type Term Value p adj.p Value p adj.p Value p adj.p
Main eﬀects Intercept 3.38 2.98 3.46
CpG 0.40 0 0 0.17 0 0 0.04 0.2702 1
Lox 0.42 0 0 0.12 0.0001 0.0005 0.26 0 0
R848 0.34 0 0 0.00 0.8678 1 0.15 0.0002 0.0027
rs179008 TT 0.03 0.7221 1 −0.03 0.4586 1 −0.06 0.3897 1
rs179008 TA −0.34 0.0009 0.0083 −0.05 0.2159 0.8635 −0.11 0.0784 0.6268
SexM −0.20 0.0096 0.0671 −0.08 0.0366 0.1830 0.09 0.0460 0.4137
Age 0.00 0.0785 0.3926 0.00 0.4712 1 0.00 0.7196 1
Interactions CpG: rs179008 TT −0.03 0.7356 1 – – – 0.06 0.3835 1
Lox: rs179008 TT 0.09 0.2728 1 – – – 0.05 0.4535 1
R848: rs179008 TT −0.08 0.3737 1 – – – 0.09 0.1932 1
CpG: rs179008 TA 0.20 0.0129 0.0773 – – – 0.10 0.1369 0.9582
Lox: rs179008 TA 0.26 0.0013 0.0103 – – – 0.23 0.0010 0.0101
R848: rs179008 TA 0.32 0.0001 0.0010 – – – 0.23 0.0007 0.0082
Main eﬀects and interactions signiﬁcant (p< 0.05) after applying multiple testing correction are in bold.
Fig. 3. Interaction of SNP rs179008 with TLR induced upregulation of maturation markers on pDCs from healthy donors. (A & B) Fold change (FC) in log
mean ﬂuorescence intensity of CD40 (A) and CD86 (B) on pDCs from healthy donors upon TLR ligation compared to incubation with medium only (i.e. log(TLR)-log
(medium)). Data was grouped according to TLR rs179008 genotype and colored according to sex of the donor (males in black, females in red). P-values displayed
represent the (multiple testing corrected) adjusted p-values displayed in Table 2 for the interaction between the genotypes and TLR-ligand induced upregulation of
each surface marker. **p < 0.01, *p < 0.05. Non-signiﬁcant results are not shown. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the Web version of this article.)
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Table 3
Interaction of sex with TLR-ligand induced pDC maturation in healthy individuals.
CD40 CD80 CD86
Sex LRT p- value: 0.0039 0.0001 0
Term Value p adj.p Value p adj.p Value p adj.p
Main eﬀects Intercept 3.25 2.93 3.37
CpG 0.47 0 0 0.15 0 0.0002 0.11 0.0026 0.0077
Lox 0.56 0 0 0.20 0 0 0.43 0 0
R848 0.51 0 0 0.06 0.0838 0.3353 0.32 0 0
SexM −0.02 0.8177 0.8818 0.01 0.7935 1 0.21 0.0001 0.0004
Age 0.00 0.1291 0.3872 0.00 0.8484 1 0.00 0.6595 0.6595
Interactions CpG: Sex M −0.05 0.4409 0.8818 0.03 0.6066 1 −0.06 0.2919 0.5838
Lox: Sex M −0.13 0.0569 0.2276 −0.18 0.0014 0.0082 −0.25 0 0
R848: Sex M −0.24 0.0008 0.0041 −0.16 0.0045 0.0225 −0.22 0.0001 0.0003
Main eﬀects and interactions signiﬁcant (p< 0.05) after applying multiple testing correction are in bold.
Fig. 4. Interaction of sex with TLR-ligand induced pDC surface marker upregulation. Fold change (FC) in log mean ﬂuorescence intensity of CD40, CD80 and
CD86 on pDCs from healthy donors upon TLR ligation compared to incubation with medium only (i.e. log(TLR)-log (medium)). Data are grouped according to sex
and colored according to rs79008 SNP (Legend). P-values displayed represent the (multiple testing corrected) adjusted p-values displayed in Table 3 for the
interaction between sex and TLR-ligand induced upregulation of each surface marker. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Non-signiﬁcant
results are not shown.
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CD40, which is mostly expressed on antigen presenting cells. Its ligand
is expressed on activated T cells, endothelial cells and platelets (re-
viewed in (Elgueta et al., 2009)). On pDCs, CD40 ligation has been
described to augment the production of IL-6, thereby facilitating gen-
eration of antibody producing plasma cells (Jego et al., 2003). Fur-
thermore, CD40 signaling can aid eﬀective activation of T cells or
prevent T cell exhaustion (Krug et al., 2001; Fonteneau et al., 2003; Tel
et al., 2013; Fuse et al., 2009; Isogawa et al., 2013). In CHB patients low
and exhausted T cells are consistently observed and held responsible for
the inability to clear HBV (Ferrari et al., 1990; Jung et al., 1991; Boni
et al., 2007, 2012; Bertoletti and Ferrari, 2016). In CHB patients and
individuals homozygous for rs179008 less induction of CD40 may thus
aﬀect the ability of pDCs to drive adaptive immune responses and could
facilitate T cell exhaustion. Simultaneous low induction of CD86 and
CD80 may further limit adaptive responses.
Taken together, our study indicates that rs179008 genotype may be
relevant for the immune response against HBV and highlights that TLR7
induced pDC maturation is aﬀected by sex, TLR7 genotypic variation
and chronic viral infection. These ﬁndings provide important insight in
the variation in TLR7 responses in healthy and diseased individuals
which is of relevance for the further clinical development and evalua-
tion of TLR7-based therapies.
Table 4
Interaction of Sex with TLR-ligand induced pDC maturation in healthy individuals carrying the WT A(A) rs179008 allele only.
CD40 CD80 CD86
Sex LRT p-value in A & AA only: 0.2352 0.0073 0.0152
Term Value p adj.p Value p adj.p Value p adj.p
Main eﬀects Intercept 3.49 2.94 3.46
CpG 0.40 0 0 0.18 0.0019 0.0133 0.07 0.2182 0.6545
Lox 0.42 0 0 0.20 0.0005 0.0040 0.36 0 0
R848 0.34 0 0 0.08 0.1746 0.6983 0.23 0.0001 0.0004
SexM −0.18 0.0831 0.1663 0.04 0.6106 1 0.18 0.0098 0.0500
Age 0.00 0.7225 0.7225 0.00 0.6928 1 −0.00 0.7572 1
Interactions CpG: Sex M – – – 0.03 0.7258 1 −0.05 0.5318 1
Lox: Sex M – – – −0.20 0.0118 0.0692 −0.21 0.0083 0.0500
R848: Sex M – – – −0.20 0.0115 0.0692 −0.17 0.0263 0.1051
Main eﬀects and interactions signiﬁcant (p< 0.05) after applying multiple testing correction are in bold.
Fig. 5. Eﬀect of TLR ligation on maturation markers on pDCs from HBV patients and healthy individuals. A)Mean ﬂuorescent intensities (MFI) of CD40, CD80
and CD86 after 24 h in the presence of absence of indicated TLR-ligands or medium alone for healthy individual (HC) and HBV patient-derived pDCs. P-values
comparing healthy and HBV for all conditions by unpaired t-tests on log transformed data. *p < 0.05. Non-signiﬁcant p-values are not shown (B) Fold change (FC) in
log mean ﬂuorescence intensity of CD40 on pDCs from healthy donors and HBV patient upon TLR ligation compared to incubation with medium only (i.e. log(TLR)-
log (medium)). *p < 0.05 represents adjusted p-values displayed in Table 4 for the interaction between HBV status Lox induced upregulation of CD40.
Table 5
Interaction between chronic HBV infection and TLR-ligand induced pDC maturation.
CD40 CD80 CD86
HBV LRT p-value: 0.027 0.7405 0.2298
Term Value p adj.p Value p adj.p Value p adj.p
Main eﬀects Intercept 3.41 2.96 3.46
CpG 0.44 0 0 0.17 0 0 0.08 0.0013 0.0064
Lox 0.50 0 0 0.10 0 0.0001 0.30 0 0
R848 0.41 0 0 0.00 0.9490 1 0.19 0 0
CHB −0.06 0.4737 1 0.00 0.9168 1 0.07 0.0430 0.1720
Sex M −0.12 0.0423 0.2115 −0.08 0.0020 0.0098 0.05 0.1204 0.3613
Age 0.00 0.7110 1 0.00 0.1975 0.7901 0.00 0.7040 0.7040
Ethnicity Turkish 0.05 0.5726 1 −0.05 0.2085 0.7901 −0.06 0.1520 0.3613
Interactions CpG: CHB −0.05 0.3765 1 – – – – – –
Lox: CHB −0.14 0.0071 0.0498 – – – – – –
R848: CHB −0.11 0.0312 0.1873 – – – – – –
Main eﬀects and interactions signiﬁcant (p< 0.05) after applying multiple testing correction are in bold.
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